FIGURE 6.

PLE‐IL‐12‐NPs engage myeloid cells and checkpoint inhibition in the tumor and spleens. HM‐1 tumors were allowed to establish for 14 days before dosing with 10 μg IL‐12 IP in PLE‐IL‐12‐NPs, UL‐NPs, or carrier‐free and compared to vehicle control. Tissues were harvested for analysis 24 h after the third daily dose. (a–f) Immune populations found within the tumor environment (a,b,c,e) and spleen (d,f) as measured by flow cytometry. Statistical differences were measured by the Student's t test. *p < 0.05; **p < 0.01; ***p < 0.001. N = 6 (Dextrose, ULNP, LNP), N = 5 (Free IL‐12) unless reduced due to insufficient events during analysis